Sep 27, 2024 | Drug advertising, Drug costs, Pharmacy, Rebates, Study
KFF Health News warns consumers not to take TV drug ads at face value: “A 2023 study found that, among top-selling drugs, those with the lowest levels of added benefit tended to spend more on advertising to patients than doctors. ‘I worry that...
Sep 3, 2024 | Biosimilars, Cost Savings, Drug costs, GLP-1s, Humira, Mounjaro, Ozempic, Rx Costs, Savings, Trulicity, Wegovy
Humira continued to be the costliest prescription drug for self-funded health plans in 2023 by a comfortable margin, according to a recent Milliman commercial drug trends review. Used to treat a variety of conditions from Crohn’s to rheumatoid arthritis and psoriatic...
Apr 16, 2024 | Biosimilars, Cost Savings, Drug costs, Humira, MedBen Rx, Pharmacy, Prescription, Rx Costs, Savings
Last year, MedBen Rx announced a new program that would enable clients to purchase Idacio, a biosimilar version of the anti-inflammatory therapy Humira – a drug that typically costs between $6,000 and $12,000 per month depending on the dose – for under $1,000 per...
Apr 1, 2024 | Benefits preservation, Comparative Effectiveness, Cost Savings, Drug costs, MedBen Rx, Pharmacy, Pharmacy Benefits Manager (PBM), Rx Costs, Savings, Specialty Drugs, Transparency
Employers are turning away from the “big three” pharmacy benefits managers to other PBMs that offer greater transparency and lower costs, says Wharton professor of health care management Lawton Robert Burns. As one of those alternatives, MedBen Rx is...
Mar 18, 2024 | DNA, Drug costs, Drugmakers, Gene therapy, Health care costs, Rx Costs, Spending
Back in late 2022, MedBen spotlighted the growth of gene therapy, a transformative medical approach that potentially cures genetic disorders by correcting or replacing an individual’s DNA. As we noted, these therapies go beyond treatment to literally...
Mar 5, 2024 | Appropriateness Solutions, Comparative Effectiveness, Cost Savings, Drug costs, MedBen Rx, Rx Costs, Savings, Value
At January’s Benefits Advisory Conference, MedBen President & CEO Kurt Harden observed that when the Food and Drug Administration (FDA) evaluates a new drug to be approved for sale, it has to be safe and effective, but not necessarily superior to...
